Ovine desipramine antibody fragments reverse desipramine cardiovascular toxicity in the rat

被引:20
|
作者
Dart, RC [1 ]
Sidki, A [1 ]
Sullivan, JB [1 ]
Egen, NB [1 ]
Garcia, RA [1 ]
机构
[1] UNIV ARIZONA,DEPT SURG,SECT EMERGENCY MED,TUCSON,AZ
关键词
D O I
10.1016/S0196-0644(96)70265-2
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To develop a model of severe desipramine cardiovascular toxicity and to determine whether partial neutralization of the antigen by desipramine-specific Fab antibody fragments ameliorates its cardiovascular effects. Methods: We administered desipramine to rats until the QRS interval tripled in duration and mean arterial pressure (MAP) was less than 100 mm Hg. Animals were then assigned to one of six groups: (1) no treatment, (2) normal saline solution control treatment (.9% NaCl infusion equal to the volume of Fab infusion), (3) nonimmune Fab control treatment (infusion of Fab equal to that in the 9.6% neutralization treatment), (4) 9.6% desipramine Fab (infusion of ovine desipramine Fab equal to 9.6% of an equimolar neutralization), (5) 19.2% desipramine Fab, and (6) 30.0% desipramine Fab. Results: QRS-interval duration, heart rate, and MAP were recorded for 60 minutes. Animals in groups 1 through 3 demon strated slow and incomplete improvement. Animals in groups 4 through 6 showed improvement in QRS-interval duration and heart rate within 4 minutes (P<.05) compared with untreated animals. A dose-response relationship was evident; animals given the highest dose of desipramine-specific Fab showed the greatest improvement. Conclusion: Partial neutralization of desipramine by specific Fab fragments produces rapid improvement of QRS-interval duration and heart rate in a rat model of severe desipramine toxicity.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 50 条
  • [1] REVERSAL OF DESIPRAMINE TOXICITY IN RATS WITH POLYCLONAL DRUG-SPECIFIC ANTIBODY FAB FRAGMENTS
    PENTEL, PR
    ROSS, CA
    LANDON, J
    SIDKI, A
    SHELVER, WL
    KEYLER, DE
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1994, 123 (03): : 387 - 393
  • [2] DESIPRAMINE MONOCLONAL-ANTIBODY FOR QUANTITATION OF DESIPRAMINE IN SERUM
    BARTLETT, C
    JELESKO, J
    PANKEY, S
    IZUTSU, A
    KEMPE, T
    COLLINS, C
    LIN, CI
    JAKLITSCH, A
    CLINICAL CHEMISTRY, 1986, 32 (06) : 1064 - 1064
  • [3] Desipramine toxicity with terbinafine
    O'Reardon, JP
    Hetznecker, JM
    Rynn, MA
    Baldassano, CF
    Szuba, MP
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (03): : 492 - 492
  • [4] DESIPRAMINE CARDIAC TOXICITY
    CARPENTER, P
    GOBEL, FL
    HULSING, DJ
    MINNESOTA MEDICINE, 1982, 65 (04) : 231 - 234
  • [5] EFFECTS OF BLOOD-PH ON DESIPRAMINE TOXICITY IN THE RAT
    PENTEL, F
    BENOWITZ, N
    VETERINARY AND HUMAN TOXICOLOGY, 1982, 24 (04) : 297 - 297
  • [6] EFFECTS OF BLOOD-PH ON DESIPRAMINE TOXICITY IN THE RAT
    PENTEL, F
    BENOWITZ, N
    VETERINARY AND HUMAN TOXICOLOGY, 1982, 24 : 196 - 196
  • [7] EFFECTS OF SPECIFIC ANTIBODY FAB FRAGMENTS ON DESIPRAMINE PHARMACOKINETICS IN THE RAT IN-VIVO AND IN THE ISOLATED, PERFUSED LIVER
    KEYLER, DE
    LECOUTEUR, DG
    POND, SM
    STPETER, JV
    PENTEL, PR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 272 (03): : 1117 - 1123
  • [8] THE TOXICITY AND DOSE OF DESIPRAMINE HYDROCHLORIDE
    AMITAI, Y
    FRISCHER, H
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (22): : 1719 - 1720
  • [9] Lack of desipramine toxicity with citalopram
    Ashton, AK
    JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (02) : 144 - 144
  • [10] DESIPRAMINE TOXICITY AND ITS TREATMENT
    LADDU, AR
    SOMANI, P
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1969, 15 (02) : 287 - &